孵化
体外
肝细胞
低温保存
体内
化学
新陈代谢
药理学
生物
生物化学
胚胎
细胞生物学
生物技术
作者
Chi‐Chi Peng,Utkarsh Doshi,Chandra Prakash,Albert P. Li
出处
期刊:Drug Metabolism Letters
[Bentham Science Publishers]
日期:2016-02-12
卷期号:10 (1): 3-15
被引量:9
标识
DOI:10.2174/1872312809666150818111500
摘要
Objective: Development and validation of a novel assay, the Plated Hepatocyte Relay Assay (PHRA), for the determination of the metabolic fates of slowly metabolized compounds. Method: Cryopreserved human hepatocytes were cultured for 4 h followed by incubation with slowly metabolized compounds for 24 h (initial incubation). On the next day, the incubated media were collected and added to hepatocytes was similarly prepared on the day of incubation (48 h incubation; 1st relay). The procedures were repeated on the next days (72 h (2nd relay), 96 h (3rd relay), and 120 h (4th relay) incubations). Results: A proof-of-concept study with two low clearance compounds, diazepam and tolbutamide, and a validation study with 15 ultra-low clearance compounds (CLnon-renal < 1 mL/min/kg) and low clearance compounds (CLnon-renal 1- 5.1 mL/min/kg) were performed. Linear time-dependent disappearance of the parent compounds was observed for all compounds. Application of published free fraction values in combination with a correction factor with in vitro hepatic clearance results obtained with the PHRA accurately predicted in vivo hepatic clearance. Conclusion: PHRA represents a useful experimental system for the evaluation of the metabolic fates of low clearance compounds in drug development.. Keywords: Cryopreserved hepatocytes, hepatic clearance, human hepatocytes, low clearance compounds, metabolic clearance, relay assay, slowly metabolized compounds.
科研通智能强力驱动
Strongly Powered by AbleSci AI